Efficacy and Safety of Sparsentan in Patients with FSGS: Results from the Pivotal Phase 3 DUPLEX-3 Study

In the phase 3 DUPLEX trial of 371 patients with focal segmental glomerulosclerosis (FSGS), sparsentan — a single-molecule dual endothelin–angiotensin receptor antagonist — produced significantly greater and more durable proteinuria reduction than irbesartan, although the two drugs did not differ significantly on the primary eGFR-slope endpoint at 108 weeks.